Director Srinivas Akkaraju buys 244,300 KLRS shares at $4.83 ($1.2M); stock down 58.6% from 52-week high, -22.3% in 30 days.
Srinivas Akkaraju, a Director at unprofitable Kalaris Therapeutics (full-year net income: $-10,856,000.00), purchased 244,300 shares at $4.83 on 2026-05-20, bringing his holding to 19,408 shares post-transaction. The purchase represents a notable dollar commitment ($1,179,969.00) into a stock trading at $4.92 currently, down 58.6% from its 52-week high of $11.88 and off 50.8% over the past 90 days. His cross-ticker track record shows strong timing (20 prior buys averaging +197.1% 90-day returns with a 95.00% win rate), yet his single prior buy at KLRS (2025-12-18) produced a -27.7% 90-day return, indicating this ticker has not aligned with his typical execution pattern. The company's unprofitable status and continued downward price momentum provide limited fundamental support for the accumulation.